BIVV003 + ST-400

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 20/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blood and Lymphatic Diseases

Conditions

Blood and Lymphatic Diseases

Trial Timeline

Dec 21, 2021 → Jul 14, 2038

NCT ID

NCT05145062

About BIVV003 + ST-400

BIVV003 + ST-400 is a pre-clinical stage product being developed by Sangamo Therapeutics for Blood and Lymphatic Diseases. The current trial status is active. This product is registered under clinical trial identifier NCT05145062. Target conditions include Blood and Lymphatic Diseases.

What happened to similar drugs?

7 of 17 similar drugs in Blood and Lymphatic Diseases were approved

Approved (7) Terminated (6) Active (7)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

🔄Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3

✅AliskirenNovartisApproved

✅Aliskiren and HCTZNovartisApproved

🔄Beriplex® P/N (Kcentra) + Fresh frozen plasmaCSLPhase 3

🔄Fibrinogen Concentrate (Human) (FCH) + PlaceboCSLPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05145062	Pre-clinical	Active	Dec 21, 2021	Jul 14, 2038	Blood and Lymphatic Diseases

Competing Products

20 competing products in Blood and Lymphatic Diseases

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
AZD6140 + Placebo	AstraZeneca	Phase 1	29
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
Ecallantide + Placebo	Merck	Phase 2	27
HSC835	Novartis	Phase 2	35
Aliskiren	Novartis	Approved	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35